Abbott Laboratories is expanding its vascular offerings through M&A. The Abbott Park, IL-based company said it has acquired Walk Vascular for an undisclosed sum.
Walk Vascular has won FDA nods for the JETi Peripheral Thrombectomy System and next-generation JETi AIO (All In One) Peripheral Thrombectomy System. Abbott said the Thrombectomy systems would be incorporated into its existing endovascular product portfolio.
"The acquisition of Walk Vascular fits well into our leading vascular device offerings and further drives Abbott's ability to provide one-of-a-kind endovascular therapy solutions to improve patient care," said Julie Tyler, senior vice president of Abbott's vascular business. "Walk Vascular's technology provides physicians with tools to efficiently remove dangerous clots from blood vessels to improve patient care."
Abbott has been relatively quiet on the M&A front. The company took part in one of its biggest deals in early 2019. Abbott said it would acquire Cephea Valve Technologies, a company it first invested in back in 2015.
Cephea's technology is being developed to provide an option for people whose diseased mitral valves need to be replaced. The artificial valve is designed to be delivered through a vein in the leg, forgoing the need for open-heart surgery.